Title:
2-PIPERIDYL OR 2-PYRAZOLYL SUBSTITUTED PYRIMIDINE COMPOUND SERVING AS EGFR INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2023/134266
Kind Code:
A1
Abstract:
A 2-piperidyl or 2-pyrazolyl substituted pyrimidine compound, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, an isotopic variant, a tautomer, a stereoisomer, a prodrug, a polymorph, a hydrate or a solvate thereof. A pharmaceutical composition comprising the compound, and a use of the pharmaceutical composition in the treatment of diseases mediated by an EGFR protein and mutants thereof.
Inventors:
LIU BIN (CN)
GAO FENG (CN)
YUAN SHUAI (CN)
ZHAO HUI (CN)
PENG XINGZHE (CN)
LIU CHONG (CN)
SHAO NING (CN)
GUO YONGQI (CN)
WU YONGYONG (CN)
WU ZHUO (CN)
GAO FENG (CN)
YUAN SHUAI (CN)
ZHAO HUI (CN)
PENG XINGZHE (CN)
LIU CHONG (CN)
SHAO NING (CN)
GUO YONGQI (CN)
WU YONGYONG (CN)
WU ZHUO (CN)
Application Number:
PCT/CN2022/128264
Publication Date:
July 20, 2023
Filing Date:
October 28, 2022
Export Citation:
Assignee:
SUZHOU PUHE BIOPHARMA CO LTD (CN)
International Classes:
A61K31/506; C07D401/14; A61P35/00; C07D471/04; C07D491/04; C07D491/08; C07D491/10; C07D519/00
Domestic Patent References:
| WO2021133809A1 | 2021-07-01 | |||
| WO2021168074A1 | 2021-08-26 |
Foreign References:
| CN104955824A | 2015-09-30 | |||
| CN101360746A | 2009-02-04 |
Other References:
MEREDITH, S.E. ET AL.: "Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer", JOURNAL OF MEDICINAL CHEMISTRY, vol. 65, 15 July 2022 (2022-07-15), XP055959499, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.2c00704
Attorney, Agent or Firm:
LIU, SHEN & ASSOCIATES (CN)
Download PDF: